Circular RNAs in β-cell function and type 2 diabetes-related complications: a potential diagnostic and therapeutic approach

Ghasemi, Hassan; Sabati, Zolfaghar; Ghaedi, Hamid; Salehi, Zaker; Alipoor, Behnam

doi:10.1007/s11033-019-04937-x

Cited by 16 publications

(9 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other authors also suggest ncRNA-based therapy to prevent diabetic microvascular complications, for instance by addressing angiogenesis and endothelial proliferation. Indeed, MEG3 upregulation seems to lessen retinal angiogenesis [ 116 , 214 ] while circ_0005015 silencing attenuates endothelial proliferation in human retina [ 10 , 13 , 214 ]. In murine models, the inhibition of miR-143/145 significantly reduces the progression of atherosclerotic plaque [ 116 ].…”

Section: Potential Clinical Application Of Non-coding Rnasmentioning

confidence: 99%

“…In murine models, the inhibition of miR-143/145 significantly reduces the progression of atherosclerotic plaque [ 116 ]. Another promising therapeutic strategy might be represented by the inhibition of fibrosis, both by antagonizing ncRNAs with profibrotic effect (e.g., miR351 [ 216 ], miR141, circ000203 [ 10 ]) or through overexpression of antifibrotic ncRNAs (e.g., miR29 [ 216 ]). The manipulation of ncRNA expression has been also suggested in NAFLD [ 23 ].…”

Section: Potential Clinical Application Of Non-coding Rnasmentioning

confidence: 99%

“…These RNA molecules seem to regulate key developmental processes and homeostasis, metabolism, cell differentiation and growth [ 3 , 8 ]. A growing body of evidence indicates that altered expression of ncRNAs patterns (e.g., due to mutations or dysregulation) is related to the development and evolution of several diseases, including metabolic ones [ 7 , 9 , 10 ]. Major metabolic diseases such as obesity, diabetes mellitus and NAFLD, along with metabolic syndrome (MetS) and dyslipidemia, have reached epidemic proportions worldwide in the past few decades [ 11 , 12 , 13 ] with deleterious consequences, including increased morbidity and mortality [ 14 ]; hence, the necessity for a better understanding of their underlying pathophysiology.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases

Formichi

Nigi

Grieco

et al. 2021

IJMS

View full text Add to dashboard Cite

The rising prevalence of metabolic diseases related to insulin resistance (IR) have stressed the urgent need of accurate and applicable tools for early diagnosis and treatment. In the last decade, non-coding RNAs (ncRNAs) have gained growing interest because of their potential role in IR modulation. NcRNAs are variable-length transcripts which are not translated into proteins but are involved in gene expression regulation. Thanks to their stability and easy detection in biological fluids, ncRNAs have been investigated as promising diagnostic and therapeutic markers in metabolic diseases, such as type 2 diabetes mellitus (T2D), obesity and non-alcoholic fatty liver disease (NAFLD). Here we review the emerging role of ncRNAs in the development of IR and related diseases such as obesity, T2D and NAFLD, and summarize current evidence concerning their potential clinical application.

show abstract

Section: Potential Clinical Application Of Non-coding Rnasmentioning

confidence: 99%

Section: Potential Clinical Application Of Non-coding Rnasmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases

Formichi

Nigi

Grieco

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Recent emerging studies have indicated that circRNAs affect vascular endothelial cell dysfunction, T2D pathogenesis, and related complications (Table 1). 45 …”

Section: Circrnas Regulate Insulin Signalingmentioning

confidence: 99%

Circular RNAs in metabolism and metabolic disorders

et al. 2021

View full text Add to dashboard Cite

Summary Metabolic syndrome (MetS) is a serious health condition triggered by hyperglycemia, dyslipidemia, and abnormal adipose deposition. Recently, circular RNAs (circRNAs) have been proposed as key molecular players in metabolic homeostasis due to their regulatory effects on genes linked to the modulation of multiple aspects of metabolism, including glucose and lipid homeostasis. Dysregulation of circRNAs can lead to metabolic disorders, indicating that circRNAs represent plausible potential targets to alleviate metabolic abnormalities. More recently, a series of circulating circRNAs have been identified to act as both essential regulatory molecules and biomarkers for the progression of metabolism‐related disorders, including type 2 diabetes mellitus (T2DM or T2D) and cardiovascular disease (CVD). The findings of this study highlight the function of circRNAs in signaling pathways implicated in metabolic diseases and their potential as future therapeutics and disease biomarkers.

show abstract

“…Besides serving as coding template in the expression of proteins, RNA has a plethora of additional biological functions and plays a key role in several diseases such as Alzheimer, cardiovascular, Cancer, and type 2 diabetes [1], [2]. RNA can be classified into protein coding or non-coding, where about 3% of total RNA is coding for proteins (so called messenger RNA = mRNA) and the remaining 97% known as non-coding (ncRNA) or functional RNA [3].…”

Section: Introductionmentioning

confidence: 99%

A Robust and Precise ConvNet for Small Non-Coding RNA Classification (RPC-snRC)

et al. 2021

View full text Add to dashboard Cite

Small non-coding RNAs (ncRNAs) are attracting increasing attention as they are now considered potentially valuable resources in the development of new drugs intended to cure several human diseases. A prerequisite for the development of drugs targeting ncRNAs or the related pathways is the identification and correct classification of such ncRNAs. State-of-the-art small ncRNA classification methodologies use secondary structural features as input. However, such feature extraction approaches only take global characteristics into account and completely ignore co-relative effects of local structures. Furthermore, secondary structure based approaches incorporate high dimensional feature space which is computationally expensive. The present paper proposes a novel Robust and Precise ConvNet (RPC-snRC) methodology which classifies small ncRNAs into relevant families by utilizing their primary sequence. RPC-snRC methodology learns hierarchical representation of features by utilizing positioning and information on the occurrence of nucleotides. To avoid exploding and vanishing gradient problems, we use an approach similar to DenseNet in which gradient can flow straight from subsequent layers to previous layers. In order to assess the effectiveness of deeper architectures for small ncRNA classification, we also adapted two ResNet architectures having a different number of layers. Experimental results on a benchmark small ncRNA dataset show that the proposed methodology does not only outperform existing small ncRNA classification approaches with a significant performance margin of 10% but it also gives better results than adapted ResNet architectures.

show abstract

Circular RNAs in β-cell function and type 2 diabetes-related complications: a potential diagnostic and therapeutic approach

Cited by 16 publications

References 120 publications

Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases

Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases

Circular RNAs in metabolism and metabolic disorders

A Robust and Precise ConvNet for Small Non-Coding RNA Classification (RPC-snRC)

Contact Info

Product

Resources

About